LifeArc announces seed fund investment in start-up GyreOx

The funding will support a two-year programme to develop and automate GyreOx’s proprietary drug discovery platform, MACRO.

LifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines

The investment will help advance studies to validate polyproxin® molecules as potential drug candidates across a range of cancers.

LifeArc and Scottish Government Chief Scientist Office launch new funding scheme to boost translational research in Scotland

Funding aims to progress strong discovery science to a point where additional substantive funding could be secured.

LifeArc and Action Medical Research launch funding call for research into rare diseases in children

£1m for translational research projects focussed on children’s rare diseases

LifeArc appoints new Chief Investment Officer (CIO)

Graham Duce appointed to the newly created role of CIO to ensure that we have a sustainable approach to income generation

Celebrating the successes of UK translation – our 2019 annual reception

Melanie Lee, LifeArc CEO acknowledges the success of the life sciences and translational research sectors in the UK

Patients with ultra-rare bone marrow disease set to benefit from £1.15m grant from LifeArc and The Aplastic Anaemia Trust

A research grant to investigate the potential of a novel type of “personalised cellular therapy” to reverse the ultra-rare condition, aplastic anaemia

LifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases

Investment to allow Caldan to translate work on free fatty acid receptors initiated in their laboratories

Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies

The agreement will enable LifeArc to enhance our antibody drug discovery capabilities